Want to join the conversation?
Vamil Divan of Credit Suisse asks about biosimilars, on Enbrel, what's the impact of biosimilars on 2016 results. $PFE President Geno Germano answers by saying that the first biosimilar for Etanercept has been approved in Europe. The overall expectation is that there will be some modest impact in 2016 and will have a strong business in Europe.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.